2463. Post-licensure Surveillance of 9-Valent Human Papillomavirus Vaccine (9vHPV) in the Vaccine Adverse Event Reporting System (VAERS), United States, 2014–2017

BACKGROUND: 9-valent human papillomavirus vaccine (9vHPV) was licensed in December 2014 and recommended by the Advisory Committee on Immunization Practices (ACIP) in February 2015. 9vHPV is FDA-approved for females and males aged 9–26 years; ACIP recommends routine vaccination at 11–12 years and thr...

Descripción completa

Detalles Bibliográficos
Autores principales: Arana, Jorge, Su, John, Lewis, Paige, Cano, Maria, Markowitz, Lauri E, Shimabukuro, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254736/
http://dx.doi.org/10.1093/ofid/ofy210.2116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254736/
http://dx.doi.org/10.1093/ofid/ofy210.2116

Ejemplares similares